Cellular markers for prognosis in human bladder cancer will be identified and validated. The goal is to predict accurately the probability of recurrence or progression for individual tumors, thereby contributing to patient management and understanding of the pathobiology of bladder tumors. Nuclear DNA content, cytokinetics, chromatin distribution patterns, oncogene expression, and in situ cytogenetics will be quantified by image and flow cytometry. Additional markers, developed by colleagues, the marker network, or elsewhere will be evaluated when appropriate. Retrospective studies will access tissue blocks from 200 cases with known outcomes. DNA content, chromatin pattern, and oncogene expression will be quantified. The diagnostic and predictive power of these measurements will be established. Prospective studies will access 100 new patients per year. Specimens include initial surgical biopsies, urines, and bladder irrigations, and four-monthly follow-up urines and irrigations. Adequately cellular specimens will be incubated with 5-BrdUrd for cytokinetic studies. Analysis includes: cellular DNA content, proliferation index, chromatin pattern, oncogene expression, in situ cytogenetics by hybridocytochemistry, and immunocytochemical markers. Cells in urine and irrigation specimens will be pelleted and embedded: sections from these samples and from the tissue blocks will be available for subsequent analysis and for distribution to other network laboratories. In all cases, marker results will be evaluated against histologic and cytologic findings and against patient outcome in order to identify markers that accurately predict tumor recurrence, progression, and therapeutic response, and patient morbidity and mortality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA047537-03
Application #
3191232
Study Section
Pathology B Study Section (PTHB)
Project Start
1989-06-05
Project End
1992-05-31
Budget Start
1991-06-04
Budget End
1992-05-31
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Veltman, Joris A; Fridlyand, Jane; Pejavar, Sunanda et al. (2003) Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 63:2872-80
Wilhelm, Monica; Veltman, Joris A; Olshen, Adam B et al. (2002) Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 62:957-60
Moore, Lee E; Smith, Allan H; Eng, Clarence et al. (2002) Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst 94:1688-96
Orntoft, Torben F; Thykjaer, Thomas; Waldman, Frederic M et al. (2002) Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol Cell Proteomics 1:37-45
Albert, P S; McShane, L M; Shih, J H et al. (2001) Latent class modeling approaches for assessing diagnostic error without a gold standard: with applications to p53 immunohistochemical assays in bladder tumors. Biometrics 57:610-9
Muscheck, M; Abol-Enein, H; Chew, K et al. (2000) Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis 21:1721-6
Baehner, R; Magrane, G; Balassanian, R et al. (2000) Donor origin of neuroendocrine carcinoma in 2 transplant patients determined by molecular cytogenetics. Hum Pathol 31:1425-9
Hovey, R M; Chu, L; Balazs, M et al. (1998) Genetic alterations in primary bladder cancers and their metastases. Cancer Res 58:3555-60
Chudek, J; Herbers, J; Wilhelm, M et al. (1998) The genetics of renal tumors in end-stage renal failure differs from those occurring in the general population. J Am Soc Nephrol 9:1045-51
Wagner, U; Bubendorf, L; Gasser, T C et al. (1997) Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 151:753-9

Showing the most recent 10 out of 40 publications